Roche Investigating Case of PML From Recently Approved Drug

May 31, 2017

Roche released a statement saying a patient receiving its multiple sclerosis drug Ocrevus was diagnosed with a deadly brain infection after switching from another medication.

The case of progressive multifocal leukoencephalopathy was in a patient previously treated for three years with Biogen’s Tysabri, and who had received a single dose of Ocrevus.

Roche said it is assessing the source of the illness but noted MS drugs that suppress the immune system can increase the risk of serious infections. Ocrevus was approved by the FDA in March.

View today's stories